{"id":5647,"date":"2020-03-09T10:15:45","date_gmt":"2020-03-09T09:15:45","guid":{"rendered":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-har-skickat-in-ansokningar-till-regulatoriska-myndigheter-i-nederlanderna-om-start-av-klinisk-fas-2b-studie\/"},"modified":"2020-03-09T10:15:45","modified_gmt":"2020-03-09T09:15:45","slug":"stayble-har-skickat-in-ansokningar-till-regulatoriska-myndigheter-i-nederlanderna-om-start-av-klinisk-fas-2b-studie","status":"publish","type":"cision-feed","link":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-har-skickat-in-ansokningar-till-regulatoriska-myndigheter-i-nederlanderna-om-start-av-klinisk-fas-2b-studie\/","title":{"rendered":"Stayble har skickat in ans\u00f6kningar till regulatoriska myndigheter i Nederl\u00e4nderna om start av klinisk fas 2b studie."},"content":{"rendered":"<p><span style=\"font-size:10pt\"><span style=\"line-height:115%\"><span style=\"color:#3b3838\"><span style=\"font-family:tahoma,arial,helvetica,sans-serif\">M\u00e5let med den klinisk fas 2b pr\u00f6vningen \u00e4r att p\u00e5visa en s\u00e4kerhet och tolerabilitet och klinisk relevant minskning i sm\u00e4rta i patienter. Studien kommer att inkludera ca 100 patienter och genomf\u00f6ras vid ca 20 kliniker i Nederl\u00e4nderna, Ryssland och Spanien. <\/span><\/span><\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bolaget kan meddela att ett viktigt steg f\u00f6r start av klinisk fas 2b studie under Q2 har genomf\u00f6rts. Bolaget har skickat in ans\u00f6kningar till regulatoriska myndigheter samt etiska kommitt\u00e9er i Nederl\u00e4nderna samt tidigare i Ryssland. Tv\u00e5 av de tre l\u00e4nderna som Bolagets fas 2b-studie planeras att genomf\u00f6ras i. Ans\u00f6kan till spanska myndigheter ber\u00e4knas skickas in under mars.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5647"}],"collection":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed"}],"about":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/cision-feed"}],"replies":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=5647"}],"version-history":[{"count":0,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5647\/revisions"}],"wp:attachment":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=5647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}